RobertEColemanDO

PubMed

• Toxicities Following Treatment with Bisphosphonates and Receptor Activator of Nuclear Factor-κB Ligand Inhibitors in Patients with Advanced Prostate Cancer.
  Gartrell, B. A.,Coleman, R. E.,Fizazi, K.,Miller, K.,Saad, F.,Sternberg, C. N.,Galsky, M. D.> ;Eur. Urol.. 2013 May 13
• Skeletal-related events and clinical outcomes in patients with bone metastases and normal levels of osteolysis: exploratory analyses.
  Lipton, A.,Cook, R.,Brown, J.,Body, J. J.,Smith, M.,Coleman, R.> ;Clin Oncol (R Coll Radiol). 2013 Apr
• Denosumab in patients with cancer-a surgical strike against the osteoclast.
  Brown, J. E.,Coleman, R. E.> ;Nat Rev Clin Oncol. 2012 Feb
• Bone cancer in 2011: Prevention and treatment of bone metastases.
  Coleman, R.E.> ;Nat Rev Clin Oncol. 2012 Feb
• Tissue confirmation of disease recurrence in breast cancer patients: Pooled analysis of multi-centre, multi-disciplinary prospective studies.
  Amir, E., Clemons, M., Purdie, C.A., Miller, N., Quinlan, P., Geddie, W., Coleman, R.E., Freedman, O.C., Jordan, L.B., Thompson, A.M.> ;Cancer Treat Rev. 2012 Oct
• Bone turnover markers: Tools for prognosis and monitoring response to bisphosphonates?
  Lipton, A., Costa, L., Coleman, R.E.> ;Breast Dis. 2011
• Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study.
  Bliss, J.M., Kilburn, L.S., Coleman, R.E., Forbes, J.F., Coates, A.S., Jones, S.E., Jassem, J., Delozier, T., Andersen, J., Paridaens, R., van de Velde, C.H., Lonning,...> ;J Clin Oncol. 2012 Mar 1
• Combination therapy inhibits development and progression of mammary tumours in immunocompetent mice.
  Ottewell, P.D., Brown, H.K., Jones, M., Rogers, T.L., Cross, S.S., Brown, N.J., Coleman, R.E., Holen, I.> ;Breast Cancer Res Treat. 2012 Jun
• Bone health management in patients with breast cancer: Current standards and emerging strategies.
  Aapro, M.S., Coleman, R.E.> ;Breast. 2012 Feb
• 94 citations
  Targeting the Notch Ligand Jagged1 in Both Tumor Cells and Stroma in Ovarian Cancer
  Adam D. Steg, Ashwini A. Katre, Blake W. Goodman, Hee-Dong Han, Alpa M. Nick, Rebecca L. Stone, Robert E. Coleman, Ronald D. Alvarez, Gabriel Lopez-Berestein, Anil K. ...> ;Clinical Cancer Research. 2011 Sep 1
• Randomized, Phase III Trial of Sequential Epirubicin and Docetaxel Versus Epirubicin Alone in Postmenopausal Patients With Node-Positive Breast Cancer.
  Coombes, R.C., Bliss, J.M., Espie, M., Erdkamp, F., Wals, J., Tres, A., Marty, M., Coleman, R.E., Tubiana-Mathieu, N., den Boer, M.O., Wardley, A., Kilburn, L.S., Coop...> ;J Clin Oncol. 2011 Aug 20
• Bisphosphonates in oncology.
  Coleman, R.E., McCloskey, E.V.> ;Bone. 2011 Jul
• Screening for central nervous system disease in metastatic gestational trophoblastic neoplasia.
  Price, J.M., Hancock, B.W., Tidy, J., Everard, J., Coleman, R.E.> ;J Reprod Med. 2010-07-01
• Potential anticancer properties of bisphosphonates.
  Neville-Webbe, H.L., Gnant, M., Coleman, R.E.> ;Semin Oncol. 2010 Jun
• Quality of life, self-esteem, fatigue, and sexual function in young men after cancer: a controlled cross-sectional study.
  Greenfield, D.M., Walters, S.J., Coleman, R.E., Hancock, B.W., Snowden, J.A., Shalet, S.M., DeRogatis, L.R., Ross, R.M.> ;Cancer. 2010 Mar 15
• The use of a point of care device for monitoring the bone resorption biomarker urinary N-telopeptide in cancer patients with bone metastases.
  Lester, J.E., Brown, J.E., Hannon, R.A., Ellis, S.P., Horsman, J.M., Purohit, O.P., Coleman, R.E.> ;Bone. 2010-03-01
• Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model.
  Ottewell, P.D., Lefley, D.V., Cross, S.S., Evans, C.A., Coleman, R.E., Holen, I.> ;Int J Cancer. 2010-01-15
• Bisphosphonates in breast cancer: teaching an old dog new tricks.
  Winter, M.C., Coleman, R.E.> ;Curr Opin Oncol. 2009-11-01
• Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone.
  Ottewell, P.D., Woodward, J.K., Lefley, D.V., Evans, C.A., Coleman, R.E., Holen, I.> ;Mol Cancer Ther. 2009-10-01
• Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy.
  Lipton, A., Steger, G.G., Figueroa, J., Alvarado, C., Solal-Celigny, P., Body, J.J., de Boer, R., Berardi, R., Gascon, P., Tonkin, K.S., Coleman, R.E., Paterson, A.G.,...> ;Clin Cancer Res. 2008-10-15
• Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference.
  Coleman, R.E., Guise, T.A., Lipton, A., Roodman, G.D., Berenson, J.R., Body, J., Boyce, B.F., Calvi, L.M., Hadji, P., McCloskey, E.V., Saad, F., Smith, M.R., Suva, L.J...> ;Clin Cancer Res. 2008-10-15
• Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer.
  Lester, J.E., Dodwell, D., Purohit, O.P., Gutcher, S.A., Ellis, S.P., Thorpe, R., Horsman, J.M., Brown, J.E., Hannon, R.A., Coleman, R.E.> ;Clin Cancer Res. 2008-10-01
• Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.
  Ottewell, P. D., Mönkkönen, H., Jones, M., Lefley, D. V., Coleman, R. E., Holen, I.> ;J Natl Cancer Inst. 2008 Aug 20
• Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.
  Ottewell, P. D., Deux, B., Mönkkönen, H., Cross, S., Coleman, R. E., Clezardin, P., Holen, I.> ;Clin Cancer Res. 2008 Jul 15
• Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic...
  Lipton, A., Cook, R., Saad, F., Major, P., Garnero, P., Terpos, E., Brown, J.E., Coleman, R.E.> ;Cancer. 2008 Jul 1
• Join now to see all